These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 16300980)

  • 1. [Radiotherapy for PSA failure after prostatectomy: which volumes?].
    Bosset M; Maingon P; Bosset JF
    Cancer Radiother; 2006 May; 10(3):117-23. PubMed ID: 16300980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endorectal MRI assessment of local relapse after surgery for prostate cancer: A model to define treatment field guidelines for adjuvant radiotherapy in patients at high risk for local failure.
    Miralbell R; Vees H; Lozano J; Khan H; Mollà M; Hidalgo A; Linero D; Rouzaud M
    Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):356-61. PubMed ID: 17236961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome--results of a retrospective study.
    Wiegel T; Lohm G; Bottke D; Höcht S; Miller K; Siegmann A; Schostak M; Neumann K; Hinkelbein W
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1009-16. PubMed ID: 18963539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postoperative prostate-specific antigen velocity independently predicts for failure of salvage radiotherapy after prostatectomy.
    King CR; Presti JC; Brooks JD; Gill H; Spiotto MT
    Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1472-7. PubMed ID: 17935902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring system.
    Buskirk SJ; Pisansky TM; Schild SE; Macdonald OK; Wehle MJ; Kozelsky TF; Collie AC; Ferrigni RG; Myers RP; Prussak KA; Heckman MG; Crook JE; Parker AS; Igel TC
    J Urol; 2006 Sep; 176(3):985-90. PubMed ID: 16890677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Need for high radiation dose (>or=70 gy) in early postoperative irradiation after radical prostatectomy: a single-institution analysis of 334 high-risk, node-negative patients.
    Cozzarini C; Montorsi F; Fiorino C; Alongi F; Bolognesi A; Da Pozzo LF; Guazzoni G; Freschi M; Roscigno M; Scattoni V; Rigatti P; Di Muzio N
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):966-74. PubMed ID: 19619960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relapse after radical prostatectomy correlates with preoperative PSA velocity and tumor volume: results from a screening population.
    Berger AP; Deibl M; Strasak A; Bektic J; Pelzer A; Steiner H; Spranger R; Fritsche G; Bartsch G; Horninger W
    Urology; 2006 Nov; 68(5):1067-71. PubMed ID: 17095070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Salvage radiotherapy for patients with PSA relapse after radical prostatectomy: comparisons among ASTRO and Phoenix biochemical failure definitions].
    Quero L; Mongiat-Artus P; Ravery V; Hennequin V; Maylin C; Desgrandchamps F; Hennequin C
    Cancer Radiother; 2009 Jul; 13(4):267-75. PubMed ID: 19446487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
    Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
    BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective three-dimensional analysis about the impact of differences in the clinical target volume in prostate cancer irradiation on normal-tissue exposure. A potential for increasing the benefit/risk ratio.
    Hille A; Töws N; Schmidberger H; Hess CF
    Strahlenther Onkol; 2005 Dec; 181(12):789-95. PubMed ID: 16362789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low pre-radiotherapy prostate-specific antigen level is a significant predictor of treatment success for postoperative radiotherapy in patients with prostate cancer.
    Sasaki T; Nakamura K; Shioyama Y; Ohga S; Toba T; Urashima Y; Yoshitake T; Terashima H; Koga H; Naito S; Noma H; Komatsu K; Yamaguchi A; Hiratsuka Y; Hirano T; Hanada K; Abe M; Fujisawa Y; Honda H
    Anticancer Res; 2006; 26(3B):2367-74. PubMed ID: 16821618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiation rescue for biochemical failure after surgery for prostate cancer: predictive parameters and an assessment of contemporary predictive models.
    Symon Z; Kundel Y; Sadetzki S; Oberman B; Ramon J; Laufer M; Catane R; Pfeffer MR
    Am J Clin Oncol; 2006 Oct; 29(5):446-50. PubMed ID: 17023777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical study of prostate specific antigen failure after radical prostatectomy for prostate cancer: a single center experience].
    Taue R; Takahashi M; Fukawa T; Koizumi T; Nakanishi R; Yamaguchi K; Yamamoto Y; Nakatsuji H; Kishimoto T; Izaki H; Oka N; Fukumori T; Kanayama HO
    Hinyokika Kiyo; 2009 Jan; 55(1):1-4. PubMed ID: 19227203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sooner or later? Outcome analysis of 431 prostate cancer patients treated with postoperative or salvage radiotherapy.
    Jereczek-Fossa BA; Zerini D; Vavassori A; Fodor C; Santoro L; Minissale A; Cambria R; Cattani F; Garibaldi C; Serafini F; Matei VD; de Cobelli O; Orecchia R
    Int J Radiat Oncol Biol Phys; 2009 May; 74(1):115-25. PubMed ID: 19004572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-specific antigen control with low-dose adjuvant radiotherapy for high-risk prostate cancer.
    Macdonald OK; Lee RJ; Snow G; Lee CM; Tward JD; Middleton AW; Middleton GW; Sause WT
    Urology; 2007 Feb; 69(2):295-9. PubMed ID: 17320667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Salvage radiotherapy in rising PSA after radical prostatectomy].
    Carrie C; Pommier P
    Cancer Radiother; 2007 Nov; 11(6-7):370-2. PubMed ID: 17869564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term benefits of elective radiotherapy after prostatectomy for patients with positive surgical margins.
    Teh BS; Bastasch MD; Mai WY; Kattan MW; Butler EB; Kadmon D
    J Urol; 2006 Jun; 175(6):2097-101; discussion 2101-2. PubMed ID: 16697811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794.
    Swanson GP; Hussey MA; Tangen CM; Chin J; Messing E; Canby-Hagino E; Forman JD; Thompson IM; Crawford ED;
    J Clin Oncol; 2007 Jun; 25(16):2225-9. PubMed ID: 17538167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate specific antigen nadir determined using ultra-sensitive prostate specific antigen as a predictor of biochemical progression after radical prostatectomy in Japanese males.
    Kinoshita H; Kamoto T; Nishiyama H; Nakamura E; Matsuda T; Ogawa O
    Int J Urol; 2007 Oct; 14(10):930-4; discussion 934. PubMed ID: 17880291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy.
    Magheli A; Rais-Bahrami S; Peck HJ; Walsh PC; Epstein JI; Trock BJ; Gonzalgo ML
    J Urol; 2007 Oct; 178(4 Pt 1):1311-5. PubMed ID: 17698095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.